Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.
EBioMedicine. 2020 Jun;56:102822. doi: 10.1016/j.ebiom.2020.102822. Epub 2020 Jun 11.
Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In times of the Coronavirus disease 2019 (COVID-19) pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients. Uncertainty exists especially because different national medical associations publish different recommendations on the extent to which immunotherapies must be continued, monitored, or possibly switched during the current pandemic. Based on the most recently available data both about the novel coronavirus and the approved immunotherapies for neurological diseases, we provide an updated overview that includes current treatment strategies and the associated COVID-19 risk, but also the potential of immunotherapies to treat COVID-19.
免疫抑制和免疫调节是治疗神经免疫性疾病的有效方法。在 2019 年冠状病毒病（COVID-19）大流行期间，临床医生必须面对一个问题，即在神经科患者中，目前是否应该开始或停止免疫治疗。这种不确定性尤其存在，因为不同的国家医学协会对免疫治疗在当前大流行期间应在多大程度上继续、监测或可能转换有不同的建议。基于目前关于新型冠状病毒和已批准的神经疾病免疫治疗的最新数据，我们提供了一个更新的概述，包括当前的治疗策略和相关的 COVID-19 风险，以及免疫治疗治疗 COVID-19 的潜力。
